Program
enzomenib
Also written as “DSP-5336” and “Enzomenib”.
Its studies are mostly in Leukemia, Myeloid, Acute, led by Sumitomo Pharma.
Drug pageEnzomenib: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sumitomo Pharma | 21 open or running | phase 2since Jul 26, 2021 | Jul 26, 2021 | Jun 30, 2027phase 2 · NCT04988555 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 26, 2021First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT04988555 · 606 planned · United States, Belgium, Canada and more
- Feb 29, 2024Named enzomenibINNProposed as its International Nonproprietary Name in WHO's List 130 · before, DSP-5336
- Feb 6, 2026Phase 1 study in Advanced Hematologic MalignanciesNCT07444268 · 8 enrolled · United States
Ahead
- Jun 30, 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT04988555
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07444268Advanced Hematologic Malignancies · United States | 1 | Completed | Aug 11, 2026 | 8 |
| NCT04988555Leukemia, Myeloid, Acute · United States, Belgium, Canada and more | 2 | Recruiting | Jun 30, 2027 | 606 |
How it is read
Names in the registry
- “DSP-5336”, 1 entry
- “Enzomenib”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.